Updates
-
-
NeurologyLive, CMSC Offer Panel Series on Changes in MRI Guidelines for MS
NeurologyLive, a multimedia platform for specialists in that field, partnered with the Consortium of Multiple Sclerosis Centers (CMSC) for its recent video series on changes ... Read more -
Stopping Tysabri Early Tied to Active PPMS, Smoking and Depression in Patients, Study Finds
The likelihood of discontinuing treatment with Tysabri (natalizumab) is higher among patients with progressive relapsing multiple sclerosis, and those who smoke and ... Read more -
Potential Therapy, Anavex 2-73, Shows Ability to Protect Neurons and Promote Myelin in Early Tests
Anavex Life Sciences‘ investigational therapy Anavex 2-73 (blarcamesine) showed an ability to protect, repair, and induce the formation of oligodendrocytes — the cells that ... Read more -
Age, Gender, Blood Glucose Affect Immune Cells’ Response to Tecfidera in RRMS Patients, Study Reports
Immune cells from patients with relapsing-remitting multiple sclerosis (RRMS) respond differently to Tecfidera (dimethyl fumarate) based on age, gender, and serum blood glucose ... Read more
-
What can changes in grey matter mean for MS?
Sponsored Post
The brain is made up of two types of tissue: grey matter and white ... -
Novartis’ Ofatumumab for Relapsing MS Up for Possible Approval by FDA and EMA
Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ... -
MS News that Caught My Eye Last Week: New Baclofen Pump, Bone Marrow Transplant Study, Bladder Problems and Life Quality, Urinary Diversion Surgery
Flowonix’s Prometra II Pump System Receives FDA Approval for Use with Intrathecal Baclofen This ... -
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity
Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have ... -
Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports
AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) ... -
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
1st Patient Enrolled in Study of Electrical Stimulation in Treating Brain Injury
News
A first patient has been enrolled in a single-site trial to evaluate the potential of electrical stimulation, called Electroceutical Therapy, in reducing brain injury, Endonovo Therapeutics, the therapy’s developer, announced. Electroceutical Therapy is a non-invasive and wearable electronic device that uses pulsed ... Read more